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Objectives: To investigate the prevalence of
comorbidities in early rheumatoid arthritis (ERA) and
early axial spondyloarthritis (ESpA) versus the general
population.
Methods: Baseline data of 689 patients with ERA
from the Etude et Suivi des Polyarthrites
Indifférenciées Récentes (ESPOIR) cohort (age 48.2
±12.1 years, symptoms duration 14.2±14.5 weeks) and
645 patients with ESpA from Devenir des
Spondylarthropathies Indifférenciées Récentes (DESIR;
age 32.8±8.4 years, axial symptoms duration 79.0
±45.7 weeks) were analysed. Metabolic and
cardiovascular diseases (CVD), infections and
neoplasia were determined in each cohort. The
prevalence (95% CI) of several comorbidities was
compared with that in the French general population.
For patients without CVD, the 10-year risk of
developing CVD was calculated using the Framingham
and SCORE equations. The heart age was calculated
using the 2008 Framingham points system.
Results: 42% of patients with ERA and 20.3% of
patients with ESpA had at least 1 comorbidity; the
most common were arterial hypertension (AHT) and
dyslipidaemia. AHT prevalence (95% CI) in ERA
(18.2% (15.5% to 21.3%)), but not in ESpA (5.08%
(3.57% to 7.14%)), was significantly increased
(p<0.05) compared with the general population
(7.58%). Prevalence of tuberculosis history was higher
in ERA (4.7% (3.3% to 6.6%)), and ESpA (0.99%
(0.4% to 2.3%)) than in the general population
(0.02%; both p<0.05). No differences were observed in
malignancies, coronary heart disease or diabetes. In
ERA, among patients without a history of CVD, an
intermediate to high CVD risk was found. The heart
age exceeded the real age by 4.1±9.6 years in ERA and
by 2.1±7.0 years in ESpA (p<0.001).
Conclusions: We found an increased prevalence of
AHT and tuberculosis history in ERA and ESpA, and an
increased CVD risk. These results should prompt
rheumatologists to check these comorbidities early in
the disease.
INTRODUCTION
Comorbidities are frequently associated with
inﬂammatory rheumatic disorders such as
rheumatoid arthritis (RA), ankylosing spon-
dylitis (AS) and psoriatic arthritis (PsA). RA
has an increased standardised mortality ratio
largely attributable to cardiovascular (CV)
risk.1 2 An increased CV mortality and inci-
dence of CV diseases (CVD) has also been
observed in AS, although less pronounced.1
Chronic inﬂammation seems to predispose
Key messages
What is already known about this subject?
▸ Cardiovascular diseases and infections such as
tuberculosis are frequently associated with
established rheumatoid arthritis or with
spondyloarthritis.
What does this study add?
▸ The risk of comorbidities, especially cardiovas-
cular diseases and tuberculosis, is increased
even in the early stages of arthritis, as well as
after long periods of inflammation or prolonged
treatment with corticosteroids or immunosup-
pressive drugs.
How might this impact on clinical practice?
▸ Patients at risk should be identified in order to
diagnose comorbidities early and ultimately treat
risk factors early.
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patients with RA and AS3 4 to hypertension, stroke and
myocardial infarction.1 However, it has not yet been
clariﬁed if the increased CV risk is already present early
in the disease process.5 6
Chronic inﬂammation and autoimmunity are also
associated with the development of malignancy.7 Some
authors suggest that, in patients with RA, these factors
are responsible for the association with haematological
cancer, the most common RA-associated malignancy.
Haematological cancer has the highest standardised inci-
dence ratio in the ﬁrst 2 years after diagnosis.8
The increased risk of tuberculosis (TB) in patients
with RA, AS and PsA is thought to be related to the
immune disturbances caused by the disease itself, as well
as to the treatment with immunosuppressive drugs,9
including anti-tumour necrosis factor α (anti-TNFα)
therapy.10 Studies that investigated this risk usually
included patients with established diseases or with long-
term corticosteroid treatment.
While the literature is abundant in data about
comorbidities in patients with established RA and AS, it
is still not clear if these comorbidities develop over long
periods of chronic inﬂammation, or if they are already
present at diagnosis. The aim of our study was to deter-
mine the prevalence of several comorbidities in patients
with early RA (ERA) and early spondyloarthritis (ESpA),
and to compare them with prevalence rates in the
general population. This will give insight into whether
the prevalence of comorbidities is already increased
shortly after the onset of the ﬁrst symptoms, before long
periods of chronic inﬂammation or immunosuppressive
treatment. In addition, we aimed to determine the
10-year risk of developing CVD.
METHODS
This is a cross-sectional study using the baseline data
from two multicentre prospective cohorts initiated by
the French Society of Rheumatology, Etude et Suivi des
Polyarthrites Indifférenciées Récentes (ESPOIR) and
Devenir des Spondylarthropathies Indifférenciées
Récentes (DESIR).
Patients
The ESPOIR cohort included 813 patients with early
inﬂammatory arthritis from November 2002 to April
2005. The database for the present baseline analysis was
locked on 15 December 2005. Detailed information of
the study has been published previously.11 Consecutive
patients aged between 18 and 70 years who had a clin-
ical diagnosis of RA or a diagnosis of undifferentiated
arthritis with potential for progressing to RA, with onset
during the past 6 months, were selected for recruitment.
Two or more swollen joints for at least 6 weeks were
required for inclusion. No previous treatment with
disease-modifying antirheumatic drugs (DMARDs) or
glucocorticoids was allowed.11 From the ESPOIR cohort,
patients fulﬁlling the 2010 American College of
Rheumatology (ACR)/European League Against
Rheumatism (EULAR)12 or the 1987 ACR classiﬁcation
criteria for RA13 were selected for analysis (patients with
ERA).
In the DESIR study (ClinicalTrials.gov identiﬁer
NCT01648907), a total of 708 consecutive patients with
inﬂammatory back pain (IBP) were recruited between
October 2007 and April 2010. The baseline database was
locked on 12 December 2011. Detailed information of
the study has been described elsewhere.14 Brieﬂy,
patients aged over 18 and under 50 years were eligible
for inclusion if they had IBP for ≥3 months but ≤3 years
and symptoms suggestive of SpA according to the local
investigator’s assessment. Patients who had a history of
any biological therapy were excluded; corticosteroid
intake was permitted only in doses lower than 10 mg
prednisone per day and stable for at least 4 weeks prior
to recruitment.14 From DESIR, only patients who ful-
ﬁlled at least one classiﬁcation criterion set for SpA
(modiﬁed New York,15 Amor criteria,16 European
Spondylarthropathy Study Group (ESSG)17 or
Assessment of SpondyloArthritis international Society
(ASAS) classiﬁcation criteria for axial SpA)18 were
included in the analysis (patients with ESpA).
The general population data were gathered from the
statistic reports of the French National Health Insurance
Fund for the Employees (Caisse Nationale de
L’assurance Maladie des Travailleurs Salaries, CNAMTS)
for the year 2008. CNAMTS manages the health branch
of the compulsory general scheme (Régime General,
RG). The RG offers health coverage to almost 90% of
the total French population.19 20
The French general population data were also col-
lected from the L’Étude nationale nutrition santé
(ENNS).21 The ENNS was a cross-sectional survey con-
ducted in continental France in 2006–2007, which
aimed to describe the main factors of CV risk in a
sample of adults (18–74 years) residing in metropolitan
France in 2006.22 Of the adults who participated in the
survey, 2413 had clinical measures available (anthropo-
metric examination and blood pressure (BP)).
Data collected in ESPOIR
Demographical data, medical history and physical mea-
surements of patients at baseline were recorded on a
standard case report ﬁle (CRF). Data about comorbid-
ities, including CVD, TB, cancers or smoking, were
recorded as presence or absence. Physical examination
included weight, height and BP. Biological parameters
(blood count, erythrocyte sedimentation rate (ESR), C
reactive protein (CRP), lipids, glucose concentrations)
were measured using standard methods in the local
laboratory of each participating centre.
Data collected in DESIR
Social and demographic characteristics, medical history,
and main clinical and biological variables at baseline
were recorded on a standard CRF. Comorbidities, in
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particular CVD, TB and malignant diseases and
smoking, were evaluated as ever present or absent. The
physical examination included height, weight, abdom-
inal circumference and BP. The same biological para-
meters as in ESPOIR were measured locally using
standard methods.
Data collected in the French general population
The total prevalence rates of coronary heart disease
(CHD), diabetes mellitus (DM), TB and malignancies in
the adult population, as well as the data per gender and
age groups, were extracted from the CNAMTS statistics
for 2008.23 Malignancies data included both lymphoma
and solid malignancies.
The number of people with arterial hypertension
(AHT) by gender and age groups in the French popula-
tion aged 18–74 years was acquired from the ENNS
survey.
CV risk calculation
For both ESPOIR and DESIR, several CV risk markers
were calculated: low-density lipoprotein level (LDL-
cholesterol) was determined by the Friedewald et al24
equation. Pulse pressure (PP; difference between systolic
BP (SBP) and diastolic BP (DBP), normal ≤40 mm Hg),
linked to vascular damage,25 was calculated. The total
cholesterol (TChol)/high-density lipoprotein (HDL)-
cholesterol ratio (ideal ≤3.5) and the triglycerides/
HDL-cholesterol ratio (ideal ≤2), markers of CV risk
and of insulin resistance, respectively, were also calcu-
lated. Target values for traditional CV risk factors (mea-
sured on physical examination and blood tests)
recommended by European Society of Cardiology (ESC)
guidelines26 were considered normal values; these
include: BP (normal=120–129 mm Hg SBP and/or 80–
84 mm Hg DBP, high normal=130–139 mm Hg SBP
and/or 85–89 mm Hg DBP, AHT ≥140 mm Hg SBP
and/or ≥90 mm Hg DBP), TChol (normal <175 mg/
dL), LDL-cholesterol (normal <100 mg/dL).
After excluding all patients with a history of CVD
(myocardial infarction, stroke or heart failure), the
10-year risk of developing CHD and the 10-year risk of
general CVD (total CV events, including risk for stroke
or heart failure) were calculated. This was done for each
patient older than 30 years using the Framingham equa-
tions from 1998 (FRS 1998)27 for CHD risk, and from
2008 (FRS 2008) for the general CVD risk.28 Low
10-year risk is deﬁned as <10% FRS, intermediate risk
10–20% and high risk ≥20%. The ‘heart age’ or the ‘vas-
cular age’ is the age of a person with the same calcu-
lated CV risk, but whose risk factors were all within
normal ranges. This was calculated using the
Framingham 2008 points system.28 29 Finally, the 10-year
risk of fatal CVD was calculated for patients older than
40 years using the SCORE algorithms for low-risk coun-
tries.30 Low-risk level is represented by <1% SCORE,
intermediate risk 1–5% and high risk ≥5%. All three CV
risk scores were calculated because they represent
different aspects of CV risk; for readability purposes,
only FRS 2008 is presented in the main text because it
represents the broadest deﬁnition of CV risk. FRS 1998
and SCORE are presented as online supplementary
material.
Statistical analysis
The Statistical Product and Service Solutions (SPSS)
package V.20.0 was used for data analysis. Descriptive sta-
tistics were used to characterise the demographic data
and comorbidities of patients with ERA and ESpA at
baseline. Data are presented as number (percentages,
%) for qualitative variables and means (±SD) for con-
tinuous variables. The prevalence of several comorbid-
ities in patients with ERA and ESpA was compared with
the prevalence in the general population by calculating
age-speciﬁc and gender-speciﬁc prevalence ratios. In
several age and gender groups of the studied cohorts,
there were no cases, prevalence rates being thus null.
Therefore, 95% CIs with continuity correction were cal-
culated on the website http://www.vassarstats.net/,
according to the recommended method described by
Wilson.31 95% CIs were also calculated for AHT preva-
lence rates from the ENNS survey. The RG represented
91.64% of the total population of the metropolitan area
of France in 2008; thus, it was considered to be an accur-
ate representation of the population and 95% CIs were
not calculated. If the prevalence (95% CI) of comorbid-
ities in the studied cohorts did not overlap with the
prevalence (95% CI) in the general population, they
were considered signiﬁcantly different (p<0.05).
Differences in inﬂammation markers (CRP and ESR)
between patients with comorbidities and those without
comorbidities were assessed by logistic regression
adjusted for age, gender, body mass index (BMI) and
lipid values.
Differences in values of traditional CV risk factors
between men and women in the same cohort were
assessed by independent samples t test (p≤0.05 consid-
ered signiﬁcant). For ESPOIR and DESIR patients with
available CV risk scores, mean±SD scores per gender
and 5-year age groups were calculated and assigned the
corresponding level of risk. The heart age was compared
with the real age of the patients in each cohort using
paired samples t test.
RESULTS
In total, 689 patients with ERA and 645 patients with
ESpA were included in the analysis. Participant
characteristics, including demographic data and
comorbidities, are summarised in table 1.
As expected, patients with ERA were older and had a
higher percentage of women. Serum inﬂammation
markers (CRP and ESR) had higher values in patients with
ERA. In total, 42.7% of the patients with ERA and 20.3%
of the patients with ESpA had at least one comorbidity at
baseline. The most common comorbidities were AHT
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(18.1%), dyslipidaemia (17.7%), dysthyroidism (11.9%),
TB (4.6%) and malignancies (4.1%) in ERA; and dyslipi-
daemia (9.3%), AHT (5.1%) and ulcer (4%) in ESpA.
Eighty-two (12.7%) patients with ESpA had received
corticosteroids, and 87 (13.5%) had received DMARDs
—sulfasalazine (44/87), methotrexate (38/87), mesala-
zine (3/87), leﬂunomide (1/87) or hydroxychloroquine
(1/87)—whereas in patients with ERA, corticosteroids
and DMARDs were not allowed at baseline.
AHT prevalence (95%CI) in ERA (18.2% (15.5% to
21.3%)), but not in ESpA (5.08% (3.57 to 7.14)), was
signiﬁcantly increased (p<0.05) compared with the
general population (7.58%; table 2).
This increase was noticeable especially in younger
women (45–64 years), when CVD risk in the general
population is generally low. A tendency towards an
increase in prevalence compared with the general
population was also present in patients with ESpA, but
the difference was signiﬁcant only in women older than
45 years. The prevalence (95% CI) of TB was signiﬁ-
cantly higher in patients with ERA (4.7% (3.3% to
6.6%)) and ESpA (1.0% (0.4% to 2.3%)) than in the
general population (0.02%; table 3; p<0.05). The
increase was more accentuated in women than in men
for both cohorts.
There were no signiﬁcant differences for DM, CHD or
malignancies in our cohorts compared with the general
population.
In the logistic regression analysis, only CRP in ESpA
was signiﬁcantly higher in patients with AHT than in
patients without hypertension (p<0.05). There were no
differences in CRP or ESR for other comorbidities
tested, including CHD, stroke, TB, neoplasia or diabetes
(data not shown).
Regarding the values of traditional CV risk factors
(measured on clinical examination or blood tests), there
were signiﬁcant differences between men and women in
each cohort (table 4).
In patients with ERA, men had higher SBP, BMI and
glycaemia (p<0.05), and lower HDL-cholesterol
(p<0.001) compared with women, whereas women had
higher TChol levels compared with men (p<0.01). Lower
HDL-cholesterol in men led to higher lipid ratios com-
pared with women. There were no signiﬁcant differences
between smoking, LDL-cholesterol and PP levels. In
patients with ESpA, differences between genders were
similar to the ones found in ESPOIR. Values of traditional
CV risk factors were not only different between men and
women, but were also higher than normal values; this
included high normal BP and hyperlipidaemia.
There were 614 patients older than 30 years and
without a diagnosis of CVD in ESPOIR and 398 in DESIR.
All items necessary to calculate the Framingham 2008
score were available for 313 participants in ESPOIR and
for 333 in DESIR. Distribution of the FRS 2008 per age
and gender groups is shown for each cohort in table 5.
Overall, 10-year CVD risk scores were low in patients
with both ERA and ESpA (8.3±8.0% and 3.7±3.4%,
respectively). However, when patients with ERA were
divided into gender and age groups, men ≥55 years old
were found to have a high risk (FRS 2008 ≥20%) of devel-
oping CVD, and women ≥60 years old an intermediate
risk (FRS 2008 ≥10% and <20%). All ESpA gender and
age groups had low FRS 2008 risk (FRS 2008 <10%).
Details on the FRS 1998 and the SCORE distributions are
available in the online supplementary ﬁle 1 and table S1.
The mean heart age of patients with ERA between 30
and 69 years was 53.8±15.6 years (table 5), which is 4.1
±9.6 years higher than their real age (p<0.001). A similar,
although to a lesser extent, mean increase (2.1±7.0 years)
was noticed in patients with ESpA (p<0.001), resulting in
a mean heart age of 39.2±8.2 years. The heart age is
usually used together with the FRS 2008 for assessment of
individual risk status of patients. As an example, a
50-year-old woman with ERA, who smokes, does not have














Male gender 161 (23.4) 304 (47.1)




Alcohol use 105 (15.2) 94 (14.6)
ESR* 30.4±24.8 14.2±16.3
CRP† 22.6±33.9 9.4±15.0‡
At least one comorbidity 294 (42.7) 131 (20.3)
Arterial hypertension 125 (18.1) 33 (5.1)
Receive treatment (%) 93.6 54.5
Hypercholesterolaemia 101 (14.7) 42 (6.5)
Receive treatment (%) 69.3 2.4
Hypertriglyceridaemia 21 (3.0) 18 (2.8)
Dysthyroidism 82 (11.9) 24 (3.7)
Previous tuberculosis 32 (4.6) 6 (0.9)
Diabetes mellitus 28 (4.1) 6 (0.9)
Previous solid
malignancies
24 (3.5) 3 (0.5)
Previous lymphoma 4 (0.6) 2 (0.3)
Coronary heart disease 6 (0.9) 0
Stroke 4 (0.6) 0
Peptic ulcer 35 (5) 26 (4)
Previous gastrointestinal
bleeding
8 (1.2) 12 (1.9)
Hepatitis B 4 (0.6) 3 (0.5)
Hepatitis C 6 (0.9) 1 (0.2)
*ESR normal <20 mm/1 h.
†CRP normal <10 mg/L (ESPOIR), <6 mg/L (DESIR).
‡N=531.
CRP, C reactive protein; DESIR, Devenir des
Spondylarthropathies Indifférenciées Récentes; ERA, early
rheumatoid arthritis; ESpA, early axial spondyloarthritis; ESR,
erythrocyte sedimentation rate; ESPOIR, Etude et Suivi des
Polyarthrites Indifférenciées Récentes.
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diabetes, has an SBP of 130 mm Hg and a TChol level of
259 mg/dL, with HDL-cholesterol of 89 mg/dL, has a cal-
culated Framingham 2008 risk of 7.5% (low risk).
However, this corresponds to a heart age of 64 years.
DISCUSSION
We determined the comorbidities at baseline in two mul-
ticentre French cohorts of ERA (ESPOIR) and ESpA
(DESIR), investigating whether they are present in the
very early stages of the diseases. Moreover, we compared
the prevalence to the French general population.
We found that comorbidities were frequent in patients
with ERA and ESpA at baseline, with AHT and dyslipi-
daemia having the highest proportions. Our results are
in line with a previous ERA study, which reported that
43% of 183 patients had at least one comorbid condi-
tion at baseline, with a frequency of 12% of AHT.32 In a
cohort of 4794 newly diagnosed patients with AS in
Taiwan, Huang et al33 described a frequency of AHT of
2.2% and dyslipidaemia of 2.6%. Interestingly, we found
fewer cases of CHD or stroke in ESPOIR patients com-
pared with other studies, and none in DESIR patients.
This is in contrast with an excess risk of cerebrovascular
Table 2 Prevalence (or CI 95%) of AHT in patients with ERA (ESPOIR) and ESpA (DESIR) compared with the French







N Prevalence (95% CI) (%) N 95% CI (%) N 95% CI (%)
Men 18–34 5 2.16 (0.80 to 5.25) 0 0 to 21.88 2 0.18 to 4.07
35–44 6 3.66 (1.50 to 8.15) 0 0 to 14.13 8 4.98 to 20.22
45–54 24 11.32 (7.53 to 16.56) 9 9.65 to 33.73 6 7.39 to 35.17
55–64 24 17.78 (11.90 to 25.50) 19 24.47 to 51.94 – –
65–74 31 32.29 (23.31 to 42.71) 5 12.99 to 61.31 – –
Women 18–34 2 0.53 (0.09 to 2.12) 1 0.06 to 6.83 3 0.42 to 5.02
35–44 4 1.52 (0.49 to 4.11) 5 1.84 to 11.72 7 2.72 to 12.69
45–54 9 2.39 (1.17 to 4.75) 19 7.49 to 18.17 7 7.00 to 30.07
55–64 29 12.55 (8.70 to 17.69) 52 28.19 to 44.29 – –
65–74 38 20.65 (15.19 to 27.36) 15 30.56 to 64.67 – –
Total 172 7.58 (6.54 to 8.77) 125 18.14 (15.37 to 21.27) 33 5.08 (3.57 to 7.14)
N, number with a diagnosis of AHT in each gender and age group.
AHT, arterial hypertension; DESIR, Devenir des Spondylarthropathies Indifférenciées Récentes; ERA, early rheumatoid arthritis; ESpA, early
axial spondyloarthritis; ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes.
Table 3 Prevalence (or CI 95%) of TB in patients with ERA (ESPOIR) and ESpA (DESIR) compared with the French








N Prevalence (%) N CI 95% (%) N CI 95% (%)
Men 20–39 1276 0.02 0 0 to 12.98 2 0.15 to 3.44
40–44 430 0.02 0 0 to 26.76 0 0 to 17.81
45–49 427 0.02 1 0.04 to 37.91 1 0.16 to 17.51
50–54 427 0.02 0 0 to 12.64 – –
55–59 470 0.03 2 1.29 to 25.76 – –
60–64 429 0.03 2 1.46 to 28.47 – –
65–69 307 0.03 0 0 to 25.35 – –
Women 20–39 1161 0.02 1 0.02 to 2.77 1 0.02 to 2.70
40–44 314 0.02 1 0.09 to 9.98 1 0.11 to 12.47
45–49 319 0.02 3 1.04 to 12.03 1 0.13 to 15.07
50–54 353 0.02 3 0.92 to 10.69 – –
55–59 348 0.02 9 5.2 to 19.41 – –
60–64 286 0.02 5 3.16 to 19.41 – –
65–69 263 0.02 5 6.53 to 36.48 – –
Total 6810 0.02 32 4.69 (3.28 to 6.63) 6 0.99 (0.4 to 2.25)
N, number with a diagnosis of tuberculosis in each gender and age group.
DESIR, Devenir des Spondylarthropathies Indifférenciées Récentes; ERA, early rheumatoid arthritis; ESpA, early axial spondyloarthritis;
ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes; TB, tuberculosis.
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disease described especially in younger patients with AS
followed up for 10.2 years.34 It is important to point out
that in the study of Szabo, patients had older age at diag-
nosis (by more than 10 years) and the development of
comorbidities is studied after AS diagnosis, whereas in
patients with ESpA we studied comorbidities developed
before diagnosis. There were other studies with results
similar to ours, including one cross-sectional study in
150 patients with SpA who did not ﬁnd any cases of cere-
brovascular disease.35
We found that the prevalence rates of AHT and TB in
patients with ERA and, to a lesser extent, in patients
with ESpA were much higher than in the general popu-
lation of similar age and gender. The increased








Men Women Men Women
N Mean±SD N Mean±SD N Mean±SD N Mean±SD
Smoking† 149 36 (24.2) 475 95 (20) 0.329 174 67 (38.5) 219 69 (31.5) 0.179
SBP 159 132.3±16.9 518 127.4±15.3 0.001 295 123.5±13.6 332 116.3±13.4 <0.001
BMI 160 25.9±4.1 527 24.9±4.6 0.015 299 24.2±5.0 340 23.7±4.4 0.186
Glycaemia 151 97.7±32.6 490 91.8±26.9 0.026 293 88.0±11.2 326 83.8±12.2 <0.001
TChol 152 193.1±41.3 501 204.5±42.0 0.003 287 185.1±45.7 319 197.7±41.6 <0.001
HDL-cholesterol 80 47.8±15.3 273 60.7±17.9 <0.001 263 49.9±14.3 301 61.3±15.5 <0.001
LDL-cholesterol 80 114.3±33.8 272 119.2±37.5 0.299 260 113.6±36.9 299 117.0±38.4 0.288
TG 152 120.6±63.8 505 105.6±60.3 0.008 287 103.9±77.0 319 100.0±80.1 0.552
TChol/HDL 80 4.2±1.3 272 3.6±1.3 <0.001 262 3.9±1.2 300 3.4±0.9 <0.001
TG/HDL 80 2.8±1.9 273 2.1±2.2 0.011 261 2.3±2 300 1.8±1.5 0.001
PP 158 53.4±11.7 518 51.6±11.8 0.094 295 48.7±10.5 332 44.0±10.2 <0.001
All variables are in mg/dL, unless stated otherwise.
*Independent samples t test.
†N (%).
BMI, body mass index; CV, cardiovascular; DESIR, Devenir des Spondylarthropathies Indifférenciées Récentes; ERA, early rheumatoid
arthritis; ESpA, early axial spondyloarthritis; ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; PP, pulse pressure; SBP, systolic blood pressure; TChol, total cholesterol; TG, triglycerides.















Men 30–34 3 4.2±1.4 39.7±4.7 54 3.0±1.4 35.4±4.8
35–39 12 5.0±2.7 41.3±6.8 40 4.1±2.3 39.0±6.6
40–44 8 7.0±4.5 45.4±10.1 22 7.1±4.2 46.0±8.7
45–49 3 7.4±1.3 49.0±3.5 30 10.0±5.3 51.8±10.2
50–54 19 13.4±8.9 56.7±10.0 – – –
55–59 14 20.0±12.9 63.7±10.5 – – –
60–64 6 24.0±11.5 69.5±8.3 – – –
65–69 7 25.2±10.1 70.9±8.6 – – –
Women 30–34 22 1.2±0.3 32.8±1.5 58 1.5±1.0 33.9±4.5
35–39 22 1.8±0.8 36.6±4.2 58 2.3±1.5 38.0±7.1
40–44 27 3.2±1.7 43.4±7.4 39 2.9±1.7 41.9±7.8
45–49 36 5.0±2.5 50.6±10.1 32 4.1±1.7 47.6±8.0
50–54 42 6.7±4.3 55.7±12.7 – – –
55–59 48 9.0±4.9 63.0±12.5 – – –
60–64 29 11.3±5.2 70.0±7.8 – – –
65–69 15 15.2±11.3 70.0±11.3 – – –
Total 313 8.3±8.0 54.2±15.1 333 3.7±3.4 40.1±8.9
N, number with FRS calculated.
DESIR, Devenir des Spondylarthropathies Indifférenciées Récentes; ERA, early rheumatoid arthritis; ESpA, early axial spondyloarthritis;
ESPOIR, Etude et Suivi des Polyarthrites Indifférenciées Récentes; FRS 2008, Framingham Risk Score (2008).
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prevalence of AHT is most striking in young patients,
especially women. In the general population, the risk of
AHT increases after the age of 55 years for men and 65
for women,36 while in our cohorts, the prevalence of
AHT was increased in women after the age of 45 years.
With regard to the prevalence of TB, there are few
studies performed in anti-TNFα naïve patients with
established RA or in patients with AS. We did not ﬁnd
studies that assess active TB history in ERA or ESpA.
Several studies showed a 2-fold to 10-fold increase in the
risk of TB among patients with established RA naïve to
anti-TNFα drugs, compared with the general popula-
tion.9 37 The rates observed in patients with ERA com-
pared with the general population conﬁrm an even
higher risk of TB in ERA than in established RA. An
increased prevalence of TB compared with the general
population was also present in patients with ESpA, but
only in women. As a possible explanation, some authors
suggest that there is an aetiological link between TB and
arthritis, proving in mouse models that Mycobacterium
tuberculosis infection promotes arthritis.38
We did not ﬁnd an increased prevalence of malignan-
cies in patients with ERA and ESpA compared with the
general population. One explanation could be that we
had no separate general population data for lymphoma,
which is known to be increased in established RA more
than solid malignancies. Another reason could be that
the risk of lymphoma increases in patients with severe
RA and persistently high disease activity over time.39
Looking into differences in inﬂammation markers
between patients with comorbidities and patients
without comorbidities, we did not ﬁnd sufﬁcient evi-
dence that inﬂammation is associated with comorbid-
ities, especially CVD, at onset of arthritis. Moreover,
comorbidities in these patients should be actively
searched and diagnosed early, in order to receive
adequate treatment.
When analysing clinical and biological values of trad-
itional CV risk factors, we found high normal BP with
overweight in ERA men and dyslipidaemia in women
with ERA and with ESpA. This increase might appear
small quantitatively compared with the recommended
ESC targets, but current evidence shows that even mild
elevations in individual risk factors can greatly inﬂuence
total CV risk, especially when several risk factors
coexist.26 Finally, we found an intermediate to high
10-year CV risk in patients with ERA older than 55 years
without CVD using three effective algorithms (FRS 1998,
FRS 2008 and SCORE) that provide complementary
information on different aspects of CV risk (CHD risk,
general CVD risk and fatal CV risk). Current ESC guide-
lines for the management of patients with CV risk
factors require the measurement of CV risk to determine
the objectives for control of the various risk factors and
the need for pharmacological intervention, in addition
to lifestyle changes.26 29 In addition, EULAR recommen-
dations highlight the critical importance of adequate
disease control in lowering CV risk. However, evidence
suggests that these recommendations are not being prac-
tised either consistently or regularly.40 41 Our results
suggest that established RA and ERA should be regarded
as a condition at high risk of CVD and that there is need
for early CV risk evaluations. One of the limitations of
any systems that estimate risk, including the
Framingham system, is that when it is applied to
middle-aged persons to calculate the absolute risk, this is
not high even though their risk factors may be high.29
As a way of solving this limitation, the heart/vascular age
was proposed. A characteristic of our cohorts, particu-
larly DESIR, is the young age of patients at inclusion. We
found that the heart age is much higher than the real
age of our patients, which translates to a higher relative
level of CV risk than the Framingham score. This may
be a useful way of expressing more clearly the CV risk to
younger patients. It may also help in the decision-
making of CV risk management and improve the com-
pliance of patients.
There are several limitations to our study. First, the
comorbid diseases recorded in ESPOIR and DESIR are
reported by patients at inclusion in the cohorts. A poten-
tial recall bias cannot be excluded; however, several
studies have conﬁrmed good agreement between self-
reported history of chronic disease and medical
records.32 42 Second, there is a trend for decrease in the
prevalence of CVD in the French population. Data from
DESIR were collected during the same period as the
general population data, but the ESPOIR data were gath-
ered prior to that date, which might have an inﬂuence
when comparing comorbidities.
In conclusion, we found an increased frequency of
comorbidities in patients with ERA or ESpA, with
increased prevalence of AHT and TB compared with the
general population. In addition, we found an increased
10-year risk in patients with ERA for developing CVD,
and increased heart age in patients with both ERA and
ESpA. These results may provide important information
to identify patients at risk, to make a diagnosis of
comorbidities early on and ultimately early treatment of
the risk factors.
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